Regioselective metabolism of cannabinoids by cytochrome P450 2J2.

Abstract

Cannabichromene (CBC) is a major non-psychoactive phytocannabinoid extracted from the cannabis plant. CBC has been shown to have anti-inflammatory effects; hence it can serve as a non-narcotic alternative to tetrahydrocannabinol (THC). Nevertheless, the metabolic pathways and metabolites of CBC have not been fully characterized. Metabolism of phytocannabinoids typically occurs via a superfamily of hemoproteins called cytochrome P450s (CYP450s). Our liquid chromatography-mass spectrometry (LC/MS) experiments show that CBC is metabolized to three different products by various human CYP450s. We identified that CYP450 2J2 (CYP2J2) predominantly produces 8'-hydroxy-CBC, an allylic hydroxide, out of the three metabolites. To investigate the CBC metabolic regioselectivity in CYP2J2, we leveraged atomistic molecular dynamics (MD) and modeling of the system. Using 200 unique conformations of CYP2J2 obtained from MD, we performed ensemble molecular docking of CBC to reveal three putative binding modes. We then assessed the stability of the obtained CBC binding modes by simulating them individually for 1 μs. Our simulations captured an average distance of 4.8 Å between the CYP2J2 heme and the 8’ carbon atom on CBC for one of the predominant binding modes, at which the allylic hydroxide metabolite occurs experimentally. At the regioselective binding mode, we observe conserved hydrogen bonding networks, mainly between the CBC hydroxyl group and the backbone oxygen of I487, as well as N379, stabilized by a water molecule. We further corroborated the stability of the regioselective binding modes by calculating relative binding free energies using alchemical free energy perturbation calculations. In conjunction, our computational and experimental methodologies elucidate a likely mode for regioselective binding and metabolism of CBC by CYP2J2, furthering the way towards accessible plant-based non-psychoactive anti-inflammatory therapeutics.